ClinicalTrials.gg
CompletedNCT05533632Updated Sep 24, 2025Results posted

Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes

A Phase 4 interventional study of Semaglutide in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 3 sites in Chile. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-24.

Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Apr 2022, registered Sep 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
104
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 163 studies testing semaglutide in Diabetes Mellitus, Type 2 — 35 open to participants now, 45 under way, 9 of them phase 3. Semaglutide · Diabetes Mellitus, Type 2.

Enrollment
82nd of 163
104 · median 104
Started
2022
with 17 others
Phase 4
40 of 163
17 open now
Registered
106th of 163
by date
Lead sponsor
89 of 163
Novo Nordisk A/S

Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, this one is the 82nd largest by enrollment, is one of 18 that started in 2022, is one of 40 in phase 4, and was the 106th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

35 of the 163 studies testing semaglutide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 163 studies testing semaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study is testing the safety and tolerability of subcutaneous semaglutide in participants with type 2 diabetes (T2D) in Chile. Participants will get a once-weekly subcutaneous injection of semaglutide in doses decided by the study doctor's criteria, according to participant's personal needs. The study will last for about 24 weeks. Participants will have 4 clinic visits and 2 phone calls. Participants will have 3 laboratory tests during the study (blood and urine samples).

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants diagnosed (clinically) with type 2 diabetes greater than equal to (≥) 90 days prior to the screening visit.
  • Stable daily dose of Oral Antidiabetic Drug (OAD) and/or insulin treatment for ≥ 60 days prior to the screening visit.
  • 7.5-10% (59-86 millimoles per mole [mmol/mol]) (both inclusive) in Visit 1.
  • Participants in which Ozempic is indicated according to approved local label.
  • Fundoscopy/Fundus photography record less than equal to (≤) 12 months.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to study intervention(s) or related products.
  • Previous participation in this study. Participation is defined as signed .
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using adequate method.
  • Participation in any clinical trial of an approved or non-approved medicinal product within 30 days before the screening visit, except Coronavirus Disease 2019 (COVID-19) related trials (this is allowed).
  • Treatment with any glucagon-like peptide-1 receptor agonists (GLP-1 RA) medication prior to the screening visit.
  • Any disorder which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
  • Family or personal history of Multiple Endocrine Neoplasia Type 2 or Medullary Thyroid Carcinoma.
  • History of pancreatitis (acute or chronic).
  • Renal impairment defined as estimated (eGFR) below 30 milliliters/minute (mL/min)/1.73 meter square (m\^2) as per MDRD-4 (Modification of Diet in Renal Disease).
  • Myocardial infarction, stroke or hospitalisation for unstable angina or within the past 180 days prior to the day of screening.
  • Participants presently classified as being in (NYHA) Class IV heart failure.
  • Planned coronary, carotid or peripheral artery revascularisation known on the day of screening.
  • Participants with (ALT) > 2.5 x upper normal limit (UNL).
  • Use of systemic treatment within 90 days prior to screening.
  • Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 90 days before the day of screening. An exception is short-term insulin treatment for acute illness for a total of ≤ 14 days.
  • Known hypoglycaemic unawareness and/or recurrent severe hypoglycaemic episodes as judged by the investigator.
  • Proliferative retinopathy or maculopathy requiring acute treatment. Verified by fundus photography or dilated fundoscopy performed within 12 months prior to screening.
  • History or presence of malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer and carcinoma in situ).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    Semaglutide

    Participants will receive semaglutide subcutaneous (s.c.) injection once weekly in a dose escalation manner for 24 weeks: 0.25 milligrams (mg) (weeks 1 to 4), 0.5 mg (weeks 5 to 12) and 0.5 mg or 1.0 mg (weeks 13 to 24).

    Drug: Semaglutide

Interventions

  • Participants will receive semaglutide s.c. injection once weekly in a dose escalation manner for 24 weeks.

06

What researchers measure

Primary outcomes

  1. Number of Adverse Events (AEs)

    Number of adverse events from baseline (Day 1) to week 24 is presented. An adverse event is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period.

    Time frame: From baseline (Day 1) up to 24 weeks

Secondary outcomes

  1. Change in Glycosylated Haemoglobin (HbA1c)

    Change in glycosylated haemoglobin (HbA1c) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

    Time frame: Baseline (week 1), week 24

  2. Participants Achieving HbA1c Less Than (<) 7.0 Percentage (%) [Yes/No]

    Participants achieving HbA1c less than 7.0% (Yes/No) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

    Time frame: From baseline (week 1) to week 24

  3. Change in Fasting Plasma Glucose (FPG) [Milligrams Per Decilitre (mg/dL)]

    Change in fasting plasma glucose (FPG) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

    Time frame: Baseline (week 1), week 24

  4. Change in Body Weight (Kilogram [Kg])

    Change in body weight from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

    Time frame: Baseline (week 1), week 24

  5. Change in Waist Circumference [Centimeter (cm)]

    Change in waist circumference from baseline (week 1) to week 24 is presented. Waist circumference is defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

    Time frame: Baseline (week 1), week 24

  6. Participants Achieving Greater Than or Equal (≥) 5% Weight Reduction (Yes/No)

    Participants achieving greater than or equal (≥) 5% weight reduction (Yes/No) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

    Time frame: From baseline (week 1) to week 24

  7. Participants Achieving Greater Than or Equal (≥) 10% Weight Reduction (Yes/No)

    Participants achieving greater than or equal (≥) 10% weight reduction (Yes/No) from baseline (week 1) to week is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

    Time frame: From baseline (week 1) to week 24

  8. Change in Total Cholesterol (mg/dL)

    Change in total cholesterol (mg/dL) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

    Time frame: Baseline (week 1), week 24

  9. Change in Low Density Lipoprotein (LDL) Cholesterol (mg/dL)

    Change in low density lipoprotein (LDL) cholesterol (mg/dL) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

    Time frame: Baseline (week 1), week 24

  10. Change in High Density Lipoprotein (HDL) Cholesterol (mg/dL)

    Change in high density lipoprotein (HDL) cholesterol (mg/dL) cholesterol from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

    Time frame: Baseline (week 1), week 24

  11. Change in Triglycerides (mg/dL)

    Change in triglycerides (mg/dL) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

    Time frame: Baseline (week 1), week 24

  12. Change in Estimated Glomerular Filtration Rate (eGFR) [Millilitre Per Minute (mL/Min) Per 1.73 Square Meter (m^2)]

    Change in estimated glomerular filtration rate (eGFR) \[millilitre per minute (mL/min) per 1.73 square meter (m\^2)\] from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

    Time frame: Baseline (week 1), week 24

  13. Change in Urine Albumin-Creatinine Ratio (UACR) [Milligram Per Gram (mg/g)]

    Change in Urine Albumin-Creatinine Ratio (UACR) \[milligram per gram (mg/g)\] from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

    Time frame: Baseline (week 1), week 24

  14. Participants Discontinued Due to Adverse Events (Treatment Discontinuation)

    Participants discontinued due to adverse events (treatment discontinuation) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period.

    Time frame: From baseline (week 1) to week 24

  15. Number of Severe Hypoglycaemic Episodes

    Number of severe hypoglycaemic episodes from baseline (week 1) to week 24 is presented. Hypoglycaemic episodes were classified as severe if there was no specific glucose threshold but were associated with severe cognitive impairment requiring external assistance for recovery. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), follow-up visit, premature discontinuation follow-up visit.

    Time frame: From baseline (week 1) to week 24

  16. Number of Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes

    Number of severe or blood glucose confirmed symptomatic hypoglycaemic episodes from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), follow-up visit, premature discontinuation follow-up visit.

    Time frame: From baseline (week 1) to week 24

  17. Number of Serious Adverse Events (SAEs)

    Number of serious adverse events (SAEs) from baseline (week 1) to week 24 is presented. An SAE is any untoward medical occurrence that fulfils at least one of the following criteria: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; important medical event. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period.

    Time frame: From baseline (week 1) to week 24

  18. Number of Adverse Reactions (ARs)

    Number of adverse reactions (ARs) from baseline (week 1) to week 24 is presented. Adverse reaction is an undesired effect of a drug or other type of treatment that can range from mild to severe and can be life-threatening. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period.

    Time frame: From baseline (week 1) to week 24

  19. Number of Serious Adverse Reactions (SARs)

    Number of serious adverse reactions (SARs) from baseline (week 1) to week 24 is presented. Serious adverse reaction is an adverse reaction that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period.

    Time frame: From baseline (week 1) to week 24

  20. Number of Suspected Unexpected Serious Adverse Reactions (SUSARs) Per Participant

    Number of suspected unexpected serious adverse reactions (SUSARs) per participant from baseline (week 1) to week 24 is presented. SUSAR is a serious adverse event which is unexpected and regarded as possibly or probably related to the trial product. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period.

    Time frame: From baseline (week 1) to week 24

  21. Change From Baseline in Heart Rate (Pulse) After 24 Weeks of Treatment

    Change from baseline in heart rate (pulse) after 24 weeks of treatment is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

    Time frame: Baseline (week 1), week 24

07

Results

Posted Feb 10, 2025

Participant flow

The trial was conducted at 3 sites in Chile.

Participant flow — Overall Study
MilestoneSemaglutide
Started104
Completed93
Not completed11
Withdrew: Participant no longer wants to participate in study, has other priorities1
Withdrew: Participant moved to another city and will not come back to santiago1
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject4
Withdrew: Adverse event4

Outcome measures

PrimaryNumber of Adverse Events (AEs)

Number of adverse events from baseline (Day 1) to week 24 is presented. An adverse event is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period.

Time frame:
From baseline (Day 1) up to 24 weeks
Reported as:
Number · Events
Number of Adverse Events (AEs)
EventsSemaglutide
Number of Adverse Events (AEs)45
SecondaryChange in Glycosylated Haemoglobin (HbA1c)

Change in glycosylated haemoglobin (HbA1c) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

Time frame:
Baseline (week 1), week 24
Reported as:
Mean · Percentage of HbA1c
Change in Glycosylated Haemoglobin (HbA1c)
Percentage of HbA1cSemaglutide
Change in Glycosylated Haemoglobin (HbA1c)-1.6 ± 1.0
SecondaryParticipants Achieving HbA1c Less Than (<) 7.0 Percentage (%) [Yes/No]

Participants achieving HbA1c less than 7.0% (Yes/No) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

Time frame:
From baseline (week 1) to week 24
Reported as:
Count of participants · Participants
Participants Achieving HbA1c Less Than (<) 7.0 Percentage (%) [Yes/No]
ParticipantsSemaglutide
Yes52
No40
SecondaryChange in Fasting Plasma Glucose (FPG) [Milligrams Per Decilitre (mg/dL)]

Change in fasting plasma glucose (FPG) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

Time frame:
Baseline (week 1), week 24
Reported as:
Mean · mg/dL
Change in Fasting Plasma Glucose (FPG) [Milligrams Per Decilitre (mg/dL)]
mg/dLSemaglutide
Change in Fasting Plasma Glucose (FPG) [Milligrams Per Decilitre (mg/dL)]-26.2 ± 61.3
SecondaryChange in Body Weight (Kilogram [Kg])

Change in body weight from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

Time frame:
Baseline (week 1), week 24
Reported as:
Mean · Kg
Change in Body Weight (Kilogram [Kg])
KgSemaglutide
Change in Body Weight (Kilogram [Kg])-5.3 ± 4.3
SecondaryChange in Waist Circumference [Centimeter (cm)]

Change in waist circumference from baseline (week 1) to week 24 is presented. Waist circumference is defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

Time frame:
Baseline (week 1), week 24
Reported as:
Mean · cm
Change in Waist Circumference [Centimeter (cm)]
cmSemaglutide
Change in Waist Circumference [Centimeter (cm)]-5.7 ± 5.7
SecondaryParticipants Achieving Greater Than or Equal (≥) 5% Weight Reduction (Yes/No)

Participants achieving greater than or equal (≥) 5% weight reduction (Yes/No) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

Time frame:
From baseline (week 1) to week 24
Reported as:
Count of participants · Participants
Participants Achieving Greater Than or Equal (≥) 5% Weight Reduction (Yes/No)
ParticipantsSemaglutide
Yes56
No36
SecondaryParticipants Achieving Greater Than or Equal (≥) 10% Weight Reduction (Yes/No)

Participants achieving greater than or equal (≥) 10% weight reduction (Yes/No) from baseline (week 1) to week is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

Time frame:
From baseline (week 1) to week 24
Reported as:
Count of participants · Participants
Participants Achieving Greater Than or Equal (≥) 10% Weight Reduction (Yes/No)
ParticipantsSemaglutide
Yes17
No75
SecondaryChange in Total Cholesterol (mg/dL)

Change in total cholesterol (mg/dL) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

Time frame:
Baseline (week 1), week 24
Reported as:
Mean · mg/dL
Change in Total Cholesterol (mg/dL)
mg/dLSemaglutide
Change in Total Cholesterol (mg/dL)-14.1 ± 26.0
SecondaryChange in Low Density Lipoprotein (LDL) Cholesterol (mg/dL)

Change in low density lipoprotein (LDL) cholesterol (mg/dL) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

Time frame:
Baseline (week 1), week 24
Reported as:
Mean · mg/dL
Change in Low Density Lipoprotein (LDL) Cholesterol (mg/dL)
mg/dLSemaglutide
Change in Low Density Lipoprotein (LDL) Cholesterol (mg/dL)-12.5 ± 26.9
SecondaryChange in High Density Lipoprotein (HDL) Cholesterol (mg/dL)

Change in high density lipoprotein (HDL) cholesterol (mg/dL) cholesterol from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

Time frame:
Baseline (week 1), week 24
Reported as:
Mean · mg/dL
Change in High Density Lipoprotein (HDL) Cholesterol (mg/dL)
mg/dLSemaglutide
Change in High Density Lipoprotein (HDL) Cholesterol (mg/dL)-1.1 ± 5.2
SecondaryChange in Triglycerides (mg/dL)

Change in triglycerides (mg/dL) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

Time frame:
Baseline (week 1), week 24
Reported as:
Mean · mg/dL
Change in Triglycerides (mg/dL)
mg/dLSemaglutide
Change in Triglycerides (mg/dL)-13.8 ± 105.2
SecondaryChange in Estimated Glomerular Filtration Rate (eGFR) [Millilitre Per Minute (mL/Min) Per 1.73 Square Meter (m^2)]

Change in estimated glomerular filtration rate (eGFR) \[millilitre per minute (mL/min) per 1.73 square meter (m\^2)\] from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

Time frame:
Baseline (week 1), week 24
Reported as:
Mean · mL/min per 1.73 m^2
Change in Estimated Glomerular Filtration Rate (eGFR) [Millilitre Per Minute (mL/Min) Per 1.73 Square Meter (m^2)]
mL/min per 1.73 m^2Semaglutide
Change in Estimated Glomerular Filtration Rate (eGFR) [Millilitre Per Minute (mL/Min) Per 1.73 Square Meter (m^2)]-1.1 ± 9.8
SecondaryChange in Urine Albumin-Creatinine Ratio (UACR) [Milligram Per Gram (mg/g)]

Change in Urine Albumin-Creatinine Ratio (UACR) \[milligram per gram (mg/g)\] from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

Time frame:
Baseline (week 1), week 24
Reported as:
Mean · mg/g
Change in Urine Albumin-Creatinine Ratio (UACR) [Milligram Per Gram (mg/g)]
mg/gSemaglutide
Change in Urine Albumin-Creatinine Ratio (UACR) [Milligram Per Gram (mg/g)]-18.0 ± 410.8
SecondaryParticipants Discontinued Due to Adverse Events (Treatment Discontinuation)

Participants discontinued due to adverse events (treatment discontinuation) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period.

Time frame:
From baseline (week 1) to week 24
Reported as:
Count of participants · Participants
Participants Discontinued Due to Adverse Events (Treatment Discontinuation)
ParticipantsSemaglutide
Participants Discontinued Due to Adverse Events (Treatment Discontinuation)4
SecondaryNumber of Severe Hypoglycaemic Episodes

Number of severe hypoglycaemic episodes from baseline (week 1) to week 24 is presented. Hypoglycaemic episodes were classified as severe if there was no specific glucose threshold but were associated with severe cognitive impairment requiring external assistance for recovery. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), follow-up visit, premature discontinuation follow-up visit.

Time frame:
From baseline (week 1) to week 24
Reported as:
Number · Episodes
Number of Severe Hypoglycaemic Episodes
EpisodesSemaglutide
Number of Severe Hypoglycaemic Episodes0
SecondaryNumber of Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes

Number of severe or blood glucose confirmed symptomatic hypoglycaemic episodes from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), follow-up visit, premature discontinuation follow-up visit.

Time frame:
From baseline (week 1) to week 24
Reported as:
Number · Episodes
Number of Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes
EpisodesSemaglutide
Severe0
Symptomatic2
SecondaryNumber of Serious Adverse Events (SAEs)

Number of serious adverse events (SAEs) from baseline (week 1) to week 24 is presented. An SAE is any untoward medical occurrence that fulfils at least one of the following criteria: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; important medical event. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period.

Time frame:
From baseline (week 1) to week 24
Reported as:
Number · Events
Number of Serious Adverse Events (SAEs)
EventsSemaglutide
Number of Serious Adverse Events (SAEs)1
SecondaryNumber of Adverse Reactions (ARs)

Number of adverse reactions (ARs) from baseline (week 1) to week 24 is presented. Adverse reaction is an undesired effect of a drug or other type of treatment that can range from mild to severe and can be life-threatening. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period.

Time frame:
From baseline (week 1) to week 24
Reported as:
Number · Events
Number of Adverse Reactions (ARs)
EventsSemaglutide
Number of Adverse Reactions (ARs)39
SecondaryNumber of Serious Adverse Reactions (SARs)

Number of serious adverse reactions (SARs) from baseline (week 1) to week 24 is presented. Serious adverse reaction is an adverse reaction that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period.

Time frame:
From baseline (week 1) to week 24
Reported as:
Number · Events
Number of Serious Adverse Reactions (SARs)
EventsSemaglutide
Number of Serious Adverse Reactions (SARs)0
SecondaryNumber of Suspected Unexpected Serious Adverse Reactions (SUSARs) Per Participant

Number of suspected unexpected serious adverse reactions (SUSARs) per participant from baseline (week 1) to week 24 is presented. SUSAR is a serious adverse event which is unexpected and regarded as possibly or probably related to the trial product. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period.

Time frame:
From baseline (week 1) to week 24
Reported as:
Number · Events
Number of Suspected Unexpected Serious Adverse Reactions (SUSARs) Per Participant
EventsSemaglutide
Number of Suspected Unexpected Serious Adverse Reactions (SUSARs) Per Participant0
SecondaryChange From Baseline in Heart Rate (Pulse) After 24 Weeks of Treatment

Change from baseline in heart rate (pulse) after 24 weeks of treatment is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

Time frame:
Baseline (week 1), week 24
Reported as:
Mean · beats per minute (bpm)
Change From Baseline in Heart Rate (Pulse) After 24 Weeks of Treatment
beats per minute (bpm)Semaglutide
Change From Baseline in Heart Rate (Pulse) After 24 Weeks of Treatment2.9 ± 11.2

Adverse events

Collected over Baseline (Day 1) up to Week 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Semaglutide0/104 (0%)1/104 (1%)18/104 (17.3%)
Most frequent serious events
Most frequent serious events
EventSemaglutide
Acute myocardial infarctionCardiac disorders1/104
Most frequent other events
Most frequent other events
EventSemaglutide
NauseaGastrointestinal disorders12/104
DiarrheaGastrointestinal disorders6/104

Baseline characteristics

Full analysis set (FAS) included all participants exposed to the study product.

Age, Continuous
Age, Continuous(Years)Semaglutide
Mean58.3 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)Semaglutide
Female83
Male21
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Semaglutide
Indigenous3
Black0
No specific ethnicity60
Unknown6
Other35
08

Study locations

3 sites
  • Servicios Médicos Godoy Limitada
    Santiago, Región Metropolitana, 7500710, Chile
  • Hospital San Juan de Dios_Santiago, Región Metropolitana
    Santiago, Región Metropolitana, 8350429, Chile
  • Hospital Padre Hurtado
    Santiago, Región Metropolitana, 8880465, Chile
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Jan 2024, 20 months.

Results were first posted in Feb 2025, 1 year after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 20 months is close to that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2022
First posted
Sep 9, 2022
StartActual
Apr 25, 2022
Primary completionActual
Jan 18, 2024
CompletionActual
Jan 18, 2024
Results first posted
Feb 10, 2025
Last update
Sep 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05533632
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Sep 9, 2022
Start date
Apr 25, 2022
Primary completion
Jan 18, 2024
Completion
Jan 18, 2024
Results posted
Feb 10, 2025
Last update
Sep 24, 2025

Study contacts

Clinical Transparency dept. 2834
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion